期刊的影响因子--文章列表

期刊文章列表
Xiangji Ying¹，Fei Shan¹，Yongning Jia¹，Zhemin Li¹，Kan Xue¹，Rulin Miao¹，Yinkui Wang¹，Zhaode Bu¹，Xiangqian Su²，Ziyu Li²，Jiafu Ji²（Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute；Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing) , Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute）.Laparoscopic vs.open lower mediastinal lymphadenectomy for Siewert type Ⅱ/Ⅲ adenocarcinoma of esophagogastric junction：An exploratory,observational,prospective,IDEAL stage2b cohort study（CLASS-10 study）[J].Chinese Journal of Cancer Research,2022,第4期 Peng Xue¹，Bingrui Wei¹，Samuel Seery²，Qing Li³，Zichen Ye¹，Yu Jiang¹，Youlin Qiao¹（Department of Epidemiology and Biostatistics,School of Population Medicine and Public Health,Chinese Academy of Medical Sciences and Peking Union Medical College；Faculty of Health and Medicine,Division of Health Research,Lancaster University；Diagnosis and Treatment for Cervical Lesions Center,Shenzhen Maternity and Child Healthcare Hospital）.Development and validation of a predictive model for endocervical curettage in patients referred for colposcopy：A multicenter retrospective diagnostic study in China[J].Chinese Journal of Cancer Research,2022,第4期 Quan Jiang^1,2,3，Chenyu Tian^1,2,3，Hao Wu⁴，Lingqiang Min^1,2,3，Hao Chen^1,2,3，Lingli Chen⁵，Fenglin Liu^1,2,3，Yihong Sun^1,2,3（Department of General Surgery,Zhongshan Hospital,Fudan University；Cancer Center,Zhongshan Hospital,Fudan University；Gastric Cancer Center,Zhongshan Hospital,Fudan University；Department of Laboratory Medicine,Zhongshan Hospital,Fudan University；Department of Pathology,Zhongshan Hospital,Fudan University）.Tertiary lymphoid structure patterns predicted anti-PD1 therapeutic responses in gastric cancer[J].Chinese Journal of Cancer Research,2022,第4期 Hanxiao Chen¹，Xiangjuan Ma²，Jie Liu³，Yu Yang⁴，Yong Fang⁵，Liping Wang⁶，Jian Fang²，Jun Zhao¹，Minglei Zhuo¹（Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing),Department I of Thoracic Oncology,Peking University Cancer Hospital &Institute；Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing),Department II of Thoracic Oncology,Peking University Cancer Hospital &Institute；Department of Pneumology,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences；Department of Oncology,the 2nd Affiliated Hospital of Harbin Medical University；Department of Oncology,Sir Run Run Shaw Hospital Zhejiang University School of Medicine；Department of Oncology,Baotou Cancer Hospital）.Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small-cell lung cancer：A real-world, multicenter,retrospective, controlled study in China[J].Chinese Journal of Cancer Research,2022,第4期 Changlong Li¹，Zhen Guan²，Yi Zhao¹，Tingting Sun¹，Zhongwu Li³，Weihu Wang⁴，Zhexuan Li⁵，Lin Wang¹，Aiwen Wu¹（Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing),Gastrointestinal Cancer Center,Peking University Cancer Hospital &Institute；Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing),Department of Radiology,Peking University Cancer Hospital &Institute；Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing),Department of Pathology,Peking University Cancer Hospital &Institute；Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing),Department of Radiation Oncology,Peking University Cancer Hospital &Institute；Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing),Department of Cancer Epidemiology,Peking University Cancer Hospital &Institute）.Predictors of pathologic complete response in patients with residual flat mucosal lesions after neoadjuvant chemoradiotherapy for locally advanced rectal cancer[J].Chinese Journal of Cancer Research,2022,第4期 Dan Lyu¹，Binliang Liu^1,2，Bo Lan¹，Xiaoying Sun³，Lixi Li¹，Jingtong Zhai¹，Haili Qian⁴，Fei Ma¹（Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College；Department of Breast Cancer Medical Oncology,Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University；Department of Medical Oncology,Cancer Hospital of Huanxing Chaoyang District；State Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College）.Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer[J].Chinese Journal of Cancer Research,2022,第4期 national health commission of the people’s republic of china（National Health Commission of the People’s Republic of China）.National guidelines for diagnosis and treatment of esophageal carcinoma 2022 in China（English version）[J].Chinese Journal of Cancer Research,2022,第4期 Limin Zou¹，Yueli Qi¹，Ling Tang¹，Yu Du¹，Meiyi Xiang¹，Xiaoming Chen²，Jun Ma³，Zhimin Yang¹（Office of Clinical Evaluation 1,Center for Drug Evaluation,National Medical Products Administration；Office of Management and Communication,Center for Drug Evaluation,National Medical Products Administration；Harbin Institute of Hematology and Oncology）.Clinical review considerations of class I PI3K inhibitors in hematolymphatic malignancies by Center for Drug Evaluation[J].Chinese Journal of Cancer Research,2022,第4期 Kuo Qi¹，Rong Liu²（The First Clinical Medical College,Inner Mongolia Medical University；Translational Cancer Research Center,Peking University First Hospital）.Subpopulation cooperation renders drug resistance of hepatobiliary tumor organoids[J].Chinese Journal of Cancer Research,2022,第4期 national health commission of the people’s republic of china（National Health Commission of the People’s Republic of China）.National guidelines for diagnosis and treatment of melanoma 2022 in China（English version）[J].Chinese Journal of Cancer Research,2022,第4期 Li Shuangxi，Ying Xiangji，Shan Fei，Jia Yongning，Li Zhemin，Xue Kan，Miao Rulin，Wang Yinkui，Bu Zhaode，Su Xiangqian，Li Ziyu，Ji Jiafu.Laparoscopic vs. open lower mediastinal lymphadenectomy for Siewert type II/III adenocarcinoma of esophagogastric junction:An exploratory, observational, prospective, IDEAL stage 2b cohort study (CLASS-10 study)[J].中国癌症研究,2022,第4期（Office of Clinical Evaluation 1，Center for Drug Evaluation，National Medical Products Administration；Office of Management and Communication，Center for Drug Evaluation，National Medical Products Administration；Harbin Institute of Hematology and Oncology）.Clinical review considerations of class Ⅰ PI3K inhibitors in hematolymphatic malignancies by Center for Drug Evaluation[J].中国癌症研究(英文版),2022,第4期 Zhongge Su，Yuhe Zhou，Xinkun Han，Ying Pang，Shuangzhi He，Lili Tang（Key Laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beiing））.Symptom burden in advanced breast cancer patients and its association between death anxiety and psychological distress[J].Chinese Journal of Cancer Research,2022,第3期 Zhiyuan Xu¹，Can Hu^1,2，Yanqiang Zhang¹，Ling Huang¹，Litao Yang¹，Jianfa Yu¹，Pengfei Yu¹，Jiahui Chen¹，Yian Du¹，Xiangdong Cheng¹（Department of Gastric Surgery；Department of Gastrointestinal Surgery）.Efficacy analysis of Cheng’s GIRAFFE reconstruction after proximal gastrectomy for adenocarcinoma of esophagogastric junction[J].Chinese Journal of Cancer Research,2022,第3期 Jiafu Ji，Zhaode Bu，Jiahui Chen（National Health Commission of the People's Republic of China；Key Laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing）；The Cancer Hospital of the University of Chinese Academy of Sciences（Zhejiang Cancer Hospital））.National guidelines for diagnosis and treatment of gastric cancer 2022 in China (English version)[J].Chinese Journal of Cancer Research,2022,第3期 Xinguang Wang，Xue Chen，Dongfeng Niu，Yang Yang，Jingyi Zhao（National Health Commission of the People’s Republic of China；Key Laboratory of Carcinogenesis and Translational Research（Ministry of Education Beijing））.National guidelines for diagnosis and treatment of breast cancer 2022 in China (English version)[J].Chinese Journal of Cancer Research,2022,第3期 Shaoyan Liu，Yansong Lin，Yiming Zhu，Lin Gui，Xiaorong Hou，Ziren Kong，Yuanlin Piao，Yuqing Sun，Hao Wang，Jian Wang，Bo Zhang，Ye Zhang，Kun Zheng（National Health Commission of the People's Republic of China；National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital；State Key Laboratory of Complex Severe and Rare Diseases；National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital；Peking Union Medical College Hospital；Peking Union Medical College Hospital；State Key Laboratory of Complex Severe and Rare Diseases；Qingdao Municipal Hospital；China Japan Friendship Hospital）.National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version)[J].Chinese Journal of Cancer Research,2022,第3期 Nan Wu，Jia Wang，Quanne Wang（National Health Commission of the People’s Republic of China；Key Laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing）；Cheeloo College of Medicine）.National guidelines for diagnosis and treatment of lung cancer 2022 in China (English version)[J].Chinese Journal of Cancer Research,2022,第3期 Baocai Xing，Kemin Jin（National Health Commission of the People’s Republic of China；Key Laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing））.National guidelines for diagnosis and treatment of pancreatic cancer 2022 in China (English version)[J].Chinese Journal of Cancer Research,2022,第3期 Yong Yang（National Health Commission of the People’s Republic of China；Key Laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing））.National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version)[J].Chinese Journal of Cancer Research,2022,第3期 Naiyi Zhang，Yidi Yuan（National Health Commission of the People's Republic of China；Key Laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing））.National guidelines for diagnosis and treatment of cervical cancer 2022 in China (English version)[J].Chinese Journal of Cancer Research,2022,第3期 Zhijun Yuan¹，Shanshan Weng²，Chenyang Ye²，Hanguang Hu²，Suzhan Zhang^3,4，Ying Yuan^2,4（Department of Radiation OncologyKey Laboratory of Cancer Prevention and InterventionMinistry of Educationthe Second Affiliated Hospital of Zhejiang University School of Medicine；Department of Medical Oncologythe Second Affiliated Hospital of Zhejiang University School of Medicine；Department of Colorectal Surgery and Oncologythe Second Affiliated Hospital of Zhejiang University School of Medicine；Cancer CenterZhejiang University）.CSCO guidelines for colorectal cancer version 2022:Updates and discussions[J].Chinese Journal of Cancer Research,2022,第2期 Zhaoming Li¹，Yue Song¹，Mingzhi Zhang¹，Yiming Wei^1,2，Hang Ruan^1,2（Department of Oncologythe First Affiliated Hospital of Zhengzhou University；State Key Laboratory of Esophageal Cancer Prevention &Treatment and Henan Key Laboratory for Esophageal Cancer Researchthe First Affiliated Hospital of Zhengzhou University）.Genomic landscape of T-cell lymphoblastic lymphoma[J].Chinese Journal of Cancer Research,2022,第2期 Bangrong Cao^1,2，Kun Mi¹，Wei Dai³，Tong Liu⁴，Tianpeng Xie³，Qiang Li³，Jinyi Lang^1,5，Yongtao Han³，Lin Peng³，Qifeng Wang^1,5（RadiationOncology Key Laboratory of Sichuan Province；Departmentof Biobank；Departmentof Thoracic Surgery；Departmentof Medical Imaging；Department of Radiation OncologySichuan Cancer Hospital &InstituteSichuan Cancer CenterSchool of MedicineUniversity of Electronic Science and Technology of China）.Prognostic and incremental value of computed tomographybased radiomics from tumor and nodal regions in esophageal squamous cell carcinoma[J].Chinese Journal of Cancer Research,2022,第2期 Heli Yang，Ke Ji，Jiafu Ji（Key Laboratory of Carcinogenesis and Translational Research （Ministry of Education/Beijing），Center of Gastrointestinal Cancer，Peking University Cancer Hospital & Institute）.Current status and perspectives of conversion therapy for advanced gastric cancer[J].Chinese Journal of Cancer Research,2022,第2期 Tongxia Wang¹，Yan Gao¹，Xi Wang²，Junrui Tian²，Yuan Li¹，Bo Yu¹，Cuiyu Huang¹，Hui Li²，Huamao Liang¹，David M.Irwin³，Huanran Tan²，Hongyan Guo¹（Department of Obstetrics and GynecologyPeking University Third Hospital；Department of PharmacologySchool of Basic Medical SciencesPeking University Health Science Center；Department of Laboratory Medicine and PathobiologyUniversity of TorontoToronto M5S1A8）.Establishment of an optimized CTC detection model consisting of EpCAM,MUC1 and WT1 in epithelial ovarian cancer and its correlation with clinical characteristics[J].Chinese Journal of Cancer Research,2022,第2期 Anqiang Wang，Zhaode Bu（Key Laboratory of Carcinogenesis and Translational Research （Ministry of Education/Beijing），Center of Gastrointestinal Cancer，Peking University Cancer Hospital & Institute）.Pan-cancer tumor-infiltrating T cells:A great hallmark in cancer immunology research[J].Chinese Journal of Cancer Research,2022,第2期 Yuehua Liang，Xiaoran Liu，Kun Li，Huiping Li（Key Laboratory of Carcinogenesis and Translational Research （Ministry of Education/Beijing），Department of Breast Oncology，Peking University Cancer Hospital & Institute）.Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triplenegative breast cancer[J].Chinese Journal of Cancer Research,2022,第2期首页上一页 1 2 3 下一页尾页共有3页，转到页

期刊文章列表